CSIMarket Company Name, Ticker, Industry, else..
 
Werewolf Therapeutics Inc   (NASDAQ: HOWL)
 
Price: $0.9660 $0.02 2.331%
Day's High: $0.9670000076293945 Week Perf: 2.66 %
Day's Low: $ 0.93 30 Day Perf: 139.7 %
Volume (M): 487,400 52 Wk High: $ 2.38
Volume (M$): $ 0 52 Wk Avg: $0.84
Open: $0.94 52 Wk Low: $0.27



 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 49
 Employees 39
 Revenues (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0

Business Description


Werewolf Therapeutics Inc is a biotechnology company focused on developing novel cancer therapeutics. The company's approach involves utilizing the body's immune system to target and eliminate cancer cells. Werewolf Therapeutics aims to create innovative therapies that can improve patient outcomes and address the limitations of current cancer treatments. They use a unique platform technology called the Werewolf Oncolytic Virus to develop their drug candidates, which are designed to selectively attack and destroy cancer cells while sparing healthy cells. The company is committed to advancing groundbreaking therapies that have the potential to transform the field of cancer treatment.


   Company Address: 200 Talcott Ave Watertown 2472 MA
   Company Phone Number: 952‑0555   Stock Exchange / Ticker: NASDAQ HOWL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        19.3% 
KPTI   -4.28%    
MGNX        6.54% 
PFE        1.75% 
SNDX        5.22% 
ZYME        3.25% 
• View Complete Report
   



Clinical Study

The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations design...

Published Fri, Nov 7 2025 3:35 PM UTC

Expanding the Horizons of Immunotherapy: Advances in Werewolf Therapeutics’ PREDATOR and INDUKINE Platforms The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations designed to enhance therapeutic efficacy while minimizing adverse effects. Werewolf Therapeutics, a prominent biotech firm, unveiled promising data from its advanced PREDATOR p...
Clinical Study

Breakthrough in Cancer Immunotherapy Werewolf Therapeutics Reports Promising Phase 1 Clinical Data for Tumor-Act...

Published Thu, Nov 7 2024 2:02 PM UTC

Werewolf Therapeutics Showcases Promising Data for WTX-330 at SITC Annual MeetingIn a significant contribution to cancer immunotherapy, Werewolf Therapeutics has presented both preclinical and clinical data on its investigational tumor-activated interleukin-12 (IL-12) prodrug, WTX-330, at the recently concluded Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting...
Clinical Study

Advancements in Cancer Treatment: Werewolf Therapeutics Showcases Promising Results wit...

Published Sat, Jun 1 2024 1:00 PM UTC

In the constant battle against cancer, new advancements in treatment options bring hope to patients and healthcare professionals alike. Werewolf Therapeutics, a biopharmaceutical company focused on developing innovative therapies for cancer and immune-mediated diseases, has been at the forefront of groundbreaking research and clinical trials. In this article, we will delve i...
Clinical Study

Werewolf Therapeutics Unveils Groundbreaking Therapeutic Data: Pioneering New Frontiers in Cancer and Immune-Mediated Diseases'

Published Thu, May 23 2024 9:00 PM UTC

Werewolf Therapeutics, a leader in innovative biotherapeutic developments, is poised to present the latest clinical trial data of its groundbreaking candidate WTX-124 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The updated results from their ongoing Phase 1/1b clinical trial will highlight WTX-124 s impressive tolerability and significant clinica...
Clinical Study

Unleashing the Potential of IL-10 INDUKINE Molecules: Werewolf Therapeutics' PREDATOR Platform Boosts Inflammatory Bowel Disease Therapy

Published Tue, Apr 23 2024 12:01 PM UTC

In a groundbreaking presentation at the AAI Annual Meeting, Werewolf Therapeutics unveiled their pioneering research, highlighting the immense potential of IL-10 INDUKINE molecules as a promising therapy for the treatment of inflammatory bowel disease (IBD). Drawing upon the transformative capabilities of their revolutionary PREDATOR platform, the scientific community witnes...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.24
Price to Sales (Expected) -
Price to Book 2.88
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.8
Working Capital Ratio 2.91
Leverage Ratio (MRQ) 0.88
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.77 $
Revenues (TTM) 0.43 $
Cash Flow (TTM) -
Cash 0.45 $
Book Value 0.34 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 538,462
Net Income per Employee (TTM) -887,513
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.36

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 34.09 %
Net Margin (MRQ) 17.48 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Werewolf Therapeutics Inc's Segments
Reportable    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.